Ge Fei-Fei, Shen Li-Pin, Yang De-Quan, Yang Xian-Cao, Li Xin, Shen Hai-Xiao, Wang Jian, Huang Shixin
Shanghai Municipal Center For Animal Disease Diagnosis, Shanghai Animal Disease Control Center, Shanghai, China.
Microbiol Spectr. 2024 Jun 14;12(8):e0044524. doi: 10.1128/spectrum.00445-24.
In 2016, a distinct branch of H3N2 canine influenza virus (CIV) emerged, which has mutations related to mammalian adaptation and has replaced previously prevalent strains. This branch poses a risk of zoonotic infection. To prevent and control H3N2 CIV, an H3N2 virus-like particle (VLP) vaccine based on the insect cell baculovirus expression system has been developed in the study. The H3N2 VLP vaccine induced high titers of hemagglutination inhibition (HI) antibodies in nasal and muscular immunized beagle dogs. Meanwhile, the VLP vaccine provided effective protection against homologous virus challenge comparable to inactivated H3N2 canine influenza virus. In addition, the intranasal H3N2 VLP vaccine induced significantly higher Th1, Th2, and Th17 immune responses, respectively (p,0.05). Importantly, intramuscular injection of VLP and inactivated H3N2 virus has complete protective effects against homologous H3N2 virus attacks. Nasal immunization with H3N2 VLP can partially protect beagles from H3N2 influenza.
A new antigenically and genetically distinct canine influenza virus (CIV) H3N2 clade possessing mutations associated with mammalian adaptation emerged in 2016 and substituted previously circulating strains. This clade poses a risk for zoonotic infection. In our study, intramuscular injection of the H3N2 virus-like particle (VLP) vaccine and inactivated H3N2 CIV confer completely sterilizing protection against homologous H3N2 canine influenza virus challenge. Our results provide further support for the possibility of developing VLP vaccines that can reliably induce immunity in animal species.
2016年，出现了一种独特的H3N2犬流感病毒（CIV）分支，其具有与适应哺乳动物相关的突变，并已取代了先前流行的毒株。该分支存在人畜共患感染的风险。为预防和控制H3N2 CIV，本研究基于昆虫细胞杆状病毒表达系统开发了一种H3N2病毒样颗粒（VLP）疫苗。H3N2 VLP疫苗在经鼻腔和肌肉免疫的比格犬中诱导产生了高滴度的血凝抑制（HI）抗体。同时，VLP疫苗提供了与灭活H3N2犬流感病毒相当的针对同源病毒攻击的有效保护。此外，经鼻H3N2 VLP疫苗分别诱导了显著更高的Th1、Th2和Th17免疫反应（p<0.05）。重要的是，肌肉注射VLP和灭活H3N2病毒对同源H3N2病毒攻击具有完全的保护作用。用H3N2 VLP进行鼻腔免疫可部分保护比格犬免受H3N2流感的侵害。
2016年出现了一种新的抗原性和基因性不同的犬流感病毒（CIV）H3N2分支，其具有与适应哺乳动物相关的突变，并取代了先前流行的毒株。该分支存在人畜共患感染的风险。在我们的研究中，肌肉注射H3N2病毒样颗粒（VLP）疫苗和灭活H3N2 CIV对同源H3N2犬流感病毒攻击提供了完全的灭菌保护。我们的结果为开发能够可靠地在动物物种中诱导免疫的VLP疫苗的可能性提供了进一步的支持。
